Mielóma multiplex: vizsgálatok itt: Spanyolország
82 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 10.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Alicante, Badalona, Barcelona, Gijón, Girona, León, L'Hospitalet de Llobregat, Madrid, Majadahonda, Málaga, Oviedo, Palma, Palma De Mallorca, Pamplona, Pozuelo de Alarcón, Santander, Santiago de Compostela, Sevilla, Terrassa, Valencia, Vitoria, Zaragoza
- Életkor
- 18 év and over
- People
- 410 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05730036 · EU 2022-501396-62-00 - 1/2. fázisTaking peopleA first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, bone marrow, lymph and lymphatic system.
- Where
- Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 16
- Run by
- Cellcentric Limited
See details and how to join2024-519498-20-00 · EU 2024-519498-20-00 - 1. fázisTaking peopleA Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
- Where
- Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Santiago de Compostela
- Életkor
- 18 év and over
- People
- 317 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT05137054 · EU 2023-506247-42-00 - 1/2. fázisTaking peopleA Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
- Where
- Badalona, Madrid, Valencia
- Életkor
- 18 év and over
- People
- 200 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05583617 · EU 2023-504484-16-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
- Where
- Alicante, Gijón, Pozuelo de Alarcón, Terrassa, Valencia
- Életkor
- 18 év and over
- People
- 915 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07222761 · EU 2024-519504-27-00 - 3. fázisTaking peopleA Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
- Where
- Alicante, Badalona, Barcelona, Granada, L'Hospitalet de Llobregat, Madrid, Murcia, Palma, Pamplona, Salamanca, Sevilla, Terrassa, Valencia, Vitoria
- Életkor
- 18 év and over
- People
- 270 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT07393282 · EU 2025-523252-31-00 - 2. fázisTaking peopleA Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Sevilla
- Életkor
- 18 év and over
- People
- 510 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04634552 · EU 2023-504581-29-00 - 4. fázisTaking peopleA Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca, Sevilla
- Életkor
- 18 év and over
- People
- 295 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05201781 · EU 2023-505530-10-00 - 3. fázisTaking peopleA Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Where
- Badalona, Barcelona, Granada, Jerez de la Frontera, L'Hospitalet de Llobregat, Madrid, Palma, Pozuelo de Alarcón, Salamanca, Terrassa, Valencia
- Életkor
- 18 év and over
- People
- 1590 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05552222 · EU 2023-503442-30-00 - 1. fázisTaking peopleA Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca
- Életkor
- 18 év and over
- People
- 180 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT05652335 · EU 2023-503679-12-00 - No phaseTaking peoplePivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia
- Where
- Madrid
- Életkor
- 10 év and over
- People
- 210 worldwide
- Run by
- Leuko Labs, Inc.
See details and how to joinNCT06323447 - 2. fázisTaking peopleA Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel
- Where
- Badalona, Barcelona, Madrid, Pamplona, Salamanca, Santander, Sevilla
- Életkor
- 18 év to 80 év
- People
- 60 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07149857 · EU 2025-521975-30-00 - 3. fázisTaking peopleA Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
- Where
- Badalona, Barcelona, Galdakao, Granada, Madrid, Pozuelo de Alarcón, Salamanca, Valencia
- Életkor
- 18 év and over
- People
- 400 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07258511 · EU 2025-522007-18-00 - 2. fázisTaking peopleA Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Barcelona, León, Madrid, Málaga, Pamplona, Valencia
- Életkor
- 18 év and over
- People
- 230 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07589634 - 3. fázisTaking peopleA Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
- Where
- Badalona, Barcelona, Cáceres, Granada, Jerez de la Frontera, León, Lugo, Madrid, Pamplona, Pozuelo de Alarcón, Salamanca, Santander, Seville, Valencia, Zaragoza
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07665450 - 3. fázisTaking peopleA Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- Where
- Barcelona, Cáceres, León, Madrid, Marbella, Murcia, Palma
- Életkor
- 18 év and over
- People
- 810 worldwide
- Run by
- Celgene
See details and how to joinNCT05519085 - 1/2. fázisTaking peopleAZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
- Where
- Badalona, Madrid, Pamplona, Salamanca
- Életkor
- 18 év and over
- People
- 226 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06106945 · EU 2023-508590-89-00 - 2. fázisTaking peopleA Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Where
- Badalona, Barcelona, Gijón, León, L'Hospitalet de Llobregat, Madrid, Murcia, Pamplona, Salamanca
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- C4 Therapeutics, Inc.
See details and how to joinNCT07284758 · EU 2025-524181-26-00 - 3. fázisTaking peopleA Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- Where
- Badalona, Granada, Madrid, Palma, Pamplona, Salamanca, Santiago de Compostela
- Életkor
- 18 év and over
- People
- 440 worldwide
- Run by
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
See details and how to joinNCT06615479 · EU 2024-515279-37-00 - 2. fázisNot yet taking people in SpanyolországElranatamab With Mezigdomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
- Where
- Albacete, Alicante, Badalona, Barcelona, Gijón, Granada, Las Palmas de Gran Canaria, Lugo, Madrid, Málaga, Murcia, Oviedo, Palma de Mallorca, Pamplona, Salamanca, Santander, Valencia, Vitoria-Gasteiz
- Életkor
- 18 év and over
- People
- 60
- Run by
- PETHEMA Foundation
See details and how to joinNCT07901868 - 3. fázisTaking peopleA Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
- Where
- Badalona, Barcelona, Cáceres, Girona, L'Hospitalet de Llobregat, Madrid, Málaga, Pamplona, Santander, Santiago de Compostela, Terrassa, Valencia
- Életkor
- 18 év and over
- People
- 1060 worldwide
- Run by
- Pfizer
See details and how to joinNCT05623020 · EU 2024-514139-50-00 - 1/2. fázisTaking peoplePhase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Where
- Barcelona, Madrid, Pamplona, Salamanca
- Életkor
- 18 év and over
- People
- 387 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03761108 · EU 2024-511454-45-00 - 1/2. fázisTaking peopleA Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- Where
- Barcelona, Cáceres, Málaga, Sevilla
- Életkor
- 18 év and over
- People
- 246 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT04973605 · EU 2023-507751-30-00 - 1. fázisTaking peopleA Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
- Where
- Barcelona, Madrid, Pamplona, Salamanca
- Életkor
- 18 év and over
- People
- 165 worldwide
- Run by
- K36 Therapeutics, Inc.
See details and how to joinNCT05651932 · EU 2022-500801-41-00 - 3. fázisTaking peopleA Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
- Where
- Badalona, Barcelona, El Palmar, Madrid, Salamanca, Santander, Seville
- Életkor
- 18 év to 130 év
- People
- 750 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07735637